Connection | Profiles RNS

Search Result Details

Back to Search Results

This page shows the details of why an item matched the keywords from your search.

Search Results

KANTARJIAN, HAGOP M

One or more keywords matched the following items that are connected to KANTARJIAN, HAGOP M

Item Type	Name
Academic Article	Ponatinib in refractory Philadelphia chromosome-positive leukemias.
Concept	Imidazoles
Academic Article	A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.
Academic Article	Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study.
Academic Article	The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia.
Academic Article	Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action.
Academic Article	Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes.
Academic Article	Philadelphia-positive acute lymphoblastic leukemia: current treatment options.
Academic Article	Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies.
Academic Article	Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts.
Academic Article	Ponatinib in Philadelphia chromosome-positive leukemias.
Academic Article	BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.
Academic Article	The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm.
Academic Article	Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.
Academic Article	Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells.
Academic Article	The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Academic Article	Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm.
Academic Article	Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor.
Academic Article	Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.
Academic Article	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.
Academic Article	Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.
Academic Article	Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
Academic Article	Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
Academic Article	Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study.
Academic Article	ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies.
Academic Article	Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis.
Academic Article	Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor.
Academic Article	Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.
Academic Article	Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting.
Academic Article	Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia?
Academic Article	Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia.
Academic Article	A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors.
Academic Article	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study.
Academic Article	Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.
Academic Article	Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia.
Academic Article	Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality.
Academic Article	Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy.
Academic Article	Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias.
Academic Article	An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
Academic Article	Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib.
Academic Article	Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee.
Academic Article	Real-life incidence of thrombotic events in leukemia patients treated with ponatinib.
Academic Article	Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia.
Academic Article	Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era.
Academic Article	Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.

Search Criteria

Imidazoles